trial

Adverse Events and Genomics in Schizophrenia

NCTId NCT01966588
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Unknown
Enrollment 100 (estimated)
Sponsored by University of British Columbia
Primary completion 2017-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Unknown
Enrollment
100 (estimated)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2013-06
Primary completion
2017-03
Eligibility
ALL

Interventions & indications

Drugs
Blood samples for whole genomic/transcriptomic sequencingUKU Side Effect Rating Scale

Sponsors

University of British ColumbiaLead Sponsor
Vancouver Coastal Health Research InstituteCollaborator
Icahn School of Medicine at Mount SinaiCollaborator

Investigators

1
Alasdair M Barr, Ph.D.Principal Investigator

Sites

1 total
Vancouver, Canada

Facts & assertions

4 sourced
Enrollment
100
Phase
NA
Primary Completion Date
2017-03
Status
UNKNOWN
relationships
The graph out of here
drug
Blood samples for whole genomic/transcriptomic sequencing
drug
UKU Side Effect Rating Scale
drug
lead_sponsor
University of British Columbia
company
collaborator
Vancouver Coastal Health Research Institute
company
Icahn School of Medicine at Mount Sinai
company
indication
Adverse Effect of Other Antipsychotics and Neuroleptics
indication
investigator
Alasdair M Barr, Ph.D.
person